A Phase III Randomized, Double Blind, Parallel Group, Placebo Controlled, Multi-centre, Multinational Study to Evaluate Efficacy and Safety of TRC150094 as an Add On to Standard of Care in Improving Cardiovascular Risk in Subjects With Diabetes, Dyslipidemia and Hypertension

Next Previous
Trial Profile

A Phase III Randomized, Double Blind, Parallel Group, Placebo Controlled, Multi-centre, Multinational Study to Evaluate Efficacy and Safety of TRC150094 as an Add On to Standard of Care in Improving Cardiovascular Risk in Subjects With Diabetes, Dyslipidemia and Hypertension

Recruiting
Phase of Trial: Phase III

Latest Information Update: 02 Apr 2018

At a glance

  • Drugs TRC 150094 (Primary)
  • Indications Dyslipidaemias
  • Focus Registrational; Therapeutic Use
  • Sponsors Torrent Pharmaceuticals

    • Most Recent Events

    • 30 Jan 2018 Status changed from not yet recruiting to recruiting.
    • 05 Jan 2018 Planned initiation date changed from 1 Dec 2017 to 1 Apr 2018.
    • 23 Aug 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top